Pathios
is an England-based biotechnology company that researches and develops novel therapeutics for the treatment of cancer... Read morePathios
is an England-based biotechnology company that researches and develops novel therapeutics for the treatment of cancer... Read more
News
Nov 20, 2024
PR Newswire
Press Release: Pathios : Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor PTT-4256 in Patients with Advanced Solid Cancers
May 15, 2024
ExploreBit
Pathios: Pathios Therapeutics Raises USD 25M Series B Financing
Apr 21, 2024
Pulse2.0
Pathios: Pathios Therapeutics: $25 Million Closed For Developing Cancer Therapies
Apr 19, 2024
FinSMEs
Pathios: Pathios Therapeutics Raises $25M in First Close of Series B Financing
Apr 18, 2024
Endpoints News
Pathios: Pathios rakes in $25M to help start trials for GPR65 inhibitor
Sep 27, 2023
BioSpace
Pathios: Pathios Therapeutics Awarded Innovate UK Grant to Evaluate First-in-Class Immunotherapy Approach in Models of Malignant Brain Cancer
Apr 17, 2023
PR Newswire
Press Release: Pathios : Pathios Therapeutics Unveils PTT-4256, a Highly Potent and Selective Inhibitor of GPR65, in Presentation at American Association for Cancer Research (AACR) Annual Meeting 2023
Nov 03, 2022
PR Newswire
Press Release: Pathios : Pathios Therapeutics to Present Preclinical Data Highlighting Potential of GPR65 Inhibition as a Powerful Anti-Tumor Immunotherapy Strategy at SITC 2022
Apr 12, 2022
FirstWord Pharma
Pathios: Pathios Therapeutics Highlights Role of GPR65 as Critical Innate Immune Checkpoint in the Human Tumor Microenvironment and Reports Anti-Tumor Activity of GPR65 Inhibition During Podium Presentation at AACR 2022
Jul 07, 2021
PR Newswire
Press Release: Pathios : Pathios Therapeutics Presents Preclinical In Vivo Proof of Concept Data for small molecule GPR65 inhibitor in human PDX cancer model
Pathios Competitors
1
2
3
4
5
6
7
8
9
10